Apogee Therapeutics, Inc. (APGE)
After hours:
| Previous close | 50.30 |
| Open | 50.42 |
| Bid | 50.69 x 100 |
| Ask | 50.95 x 100 |
| Day's range | 48.25 - 51.56 |
| 52-week range | 14.19 - 72.29 |
| Volume | |
| Avg. volume | 703,139 |
| Market cap | 2.975B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 85.80 |
Simply Wall St.With 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Apogee Therapeutics implies that they have significant influence...
ZacksApogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
GlobeNewswireApogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing every two weeks for other biologics in development Second product candidate to enter the clinic following positive interim results from Phase 1 Healthy Volunteer Trial for APG777, which exceeded all of its trial objectives Interim subcutaneous safety and pharmacokinetic data from healthy volunteers
